Call it a benefit of second guessing.

The US Food and Drug Administration, trying to open more drugs to personalization, has been relabeling products to promote the availability of molecular diagnostic tests capable of estimating patient responses to therapy. This policy continued with last week's revision of the label for Camptosar (irinotecan), a Pfizer cancer drug, to reflect links between patient response and certain mutations in the UGT1A1 gene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.